These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 37165917)

  • 1. Aberrant expression of NPPB through YAP1 and TAZ activation in mesothelioma with Hippo pathway gene alterations.
    Sato T; Akao K; Sato A; Tsujimura T; Mukai S; Sekido Y
    Cancer Med; 2023 Jun; 12(12):13586-13598. PubMed ID: 37165917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models.
    Hillen H; Candi A; Vanderhoydonck B; Kowalczyk W; Sansores-Garcia L; Kesikiadou EC; Van Huffel L; Spiessens L; Nijs M; Soons E; Haeck W; Klaassen H; Smets W; Spieser SA; Marchand A; Chaltin P; Ciesielski F; Debaene F; Chen L; Kamal A; Gwaltney SL; Versele M; Halder GA
    Mol Cancer Ther; 2024 Jan; 23(1):3-13. PubMed ID: 37748190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-occurring Mutations of Tumor Suppressor Genes,
    Tranchant R; Quetel L; Tallet A; Meiller C; Renier A; de Koning L; de Reynies A; Le Pimpec-Barthes F; Zucman-Rossi J; Jaurand MC; Jean D
    Clin Cancer Res; 2017 Jun; 23(12):3191-3202. PubMed ID: 28003305
    [No Abstract]   [Full Text] [Related]  

  • 4. Gene therapy for diffuse pleural mesotheliomas in preclinical models by concurrent expression of NF2 and SuperHippo.
    Zhu R; Liu X; Zhang X; Zhong Z; Qi S; Jin R; Gu Y; Wang Y; Ling C; Chen K; Ye D; Yu FX
    Cell Rep Med; 2024 Oct; 5(10):101763. PubMed ID: 39368484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TAZ activation by Hippo pathway dysregulation induces cytokine gene expression and promotes mesothelial cell transformation.
    Matsushita A; Sato T; Mukai S; Fujishita T; Mishiro-Sato E; Okuda M; Aoki M; Hasegawa Y; Sekido Y
    Oncogene; 2019 Mar; 38(11):1966-1978. PubMed ID: 30401981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NF2 and Canonical Hippo-YAP Pathway Define Distinct Tumor Subsets Characterized by Different Immune Deficiency and Treatment Implications in Human Pleural Mesothelioma.
    Yang H; Hall SRR; Sun B; Zhao L; Gao Y; Schmid RA; Tan ST; Peng RW; Yao F
    Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33805359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hippo pathway gene mutations in malignant mesothelioma: revealed by RNA and targeted exon sequencing.
    Miyanaga A; Masuda M; Tsuta K; Kawasaki K; Nakamura Y; Sakuma T; Asamura H; Gemma A; Yamada T
    J Thorac Oncol; 2015 May; 10(5):844-851. PubMed ID: 25902174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. YAP/TAZ activation predicts clinical outcomes in mesothelioma and is conserved in in vitro model of driver mutations.
    Cunningham R; Jia S; Purohit K; Salem O; Hui NS; Lin Y; Carragher NO; Hansen CG
    Clin Transl Med; 2023 Feb; 13(2):e1190. PubMed ID: 36740402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the Hippo Pathway Is a New Potential Therapeutic Modality for Malignant Mesothelioma.
    Sekido Y
    Cancers (Basel); 2018 Mar; 10(4):. PubMed ID: 29565815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LIM-domain protein AJUBA suppresses malignant mesothelioma cell proliferation via Hippo signaling cascade.
    Tanaka I; Osada H; Fujii M; Fukatsu A; Hida T; Horio Y; Kondo Y; Sato A; Hasegawa Y; Tsujimura T; Sekido Y
    Oncogene; 2015 Jan; 34(1):73-83. PubMed ID: 24336325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. YAP1 is essential for malignant mesothelioma tumor maintenance.
    Calvet L; Dos-Santos O; Spanakis E; Jean-Baptiste V; Le Bail JC; Buzy A; Paul P; Henry C; Valence S; Dib C; Pollard J; Sidhu S; Moll J; Debussche L; Valtingojer I
    BMC Cancer; 2022 Jun; 22(1):639. PubMed ID: 35689194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Expression and clinical significance of SETD2 in maligant pleural mesothelioma].
    Yu M; Yu M; Zhu LJ; Yuan XY; Zhang X
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2021 Feb; 39(2):91-98. PubMed ID: 33691361
    [No Abstract]   [Full Text] [Related]  

  • 13. LATS2 is a tumor suppressor gene of malignant mesothelioma.
    Murakami H; Mizuno T; Taniguchi T; Fujii M; Ishiguro F; Fukui T; Akatsuka S; Horio Y; Hida T; Kondo Y; Toyokuni S; Osada H; Sekido Y
    Cancer Res; 2011 Feb; 71(3):873-83. PubMed ID: 21245096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis.
    Tanaka K; Osada H; Murakami-Tonami Y; Horio Y; Hida T; Sekido Y
    Cancer Lett; 2017 Jan; 385():215-224. PubMed ID: 27773750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hippo pathway effectors YAP1/TAZ induce an EWS-FLI1-opposing gene signature and associate with disease progression in Ewing sarcoma.
    Rodríguez-Núñez P; Romero-Pérez L; Amaral AT; Puerto-Camacho P; Jordán C; Marcilla D; Grünewald TG; Alonso J; de Alava E; Díaz-Martín J
    J Pathol; 2020 Apr; 250(4):374-386. PubMed ID: 31880317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of MiR-31 stimulates expression of LATS2 via the hippo pathway and promotes epithelial-mesenchymal transition in esophageal squamous cell carcinoma.
    Gao Y; Yi J; Zhang K; Bai F; Feng B; Wang R; Chu X; Chen L; Song H
    J Exp Clin Cancer Res; 2017 Nov; 36(1):161. PubMed ID: 29145896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The novel potent TEAD inhibitor, K-975, inhibits YAP1/TAZ-TEAD protein-protein interactions and exerts an anti-tumor effect on malignant pleural mesothelioma.
    Kaneda A; Seike T; Danjo T; Nakajima T; Otsubo N; Yamaguchi D; Tsuji Y; Hamaguchi K; Yasunaga M; Nishiya Y; Suzuki M; Saito JI; Yatsunami R; Nakamura S; Sekido Y; Mori K
    Am J Cancer Res; 2020; 10(12):4399-4415. PubMed ID: 33415007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CADM1 associates with Hippo pathway core kinases; membranous co-expression of CADM1 and LATS2 in lung tumors predicts good prognosis.
    Ito T; Nakamura A; Tanaka I; Tsuboi Y; Morikawa T; Nakajima J; Takai D; Fukayama M; Sekido Y; Niki T; Matsubara D; Murakami Y
    Cancer Sci; 2019 Jul; 110(7):2284-2295. PubMed ID: 31069869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Malignant cells from pleural fluids in malignant mesothelioma patients reveal novel mutations.
    Sneddon S; Dick I; Lee YCG; Musk AWB; Patch AM; Pearson JV; Waddell N; Allcock RJN; Holt RA; Robinson BWS; Creaney J
    Lung Cancer; 2018 May; 119():64-70. PubMed ID: 29656754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NF2/Merlin Inactivation and Potential Therapeutic Targets in Mesothelioma.
    Sato T; Sekido Y
    Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29587439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.